Condition: Chronic Myeloid Leukemia (CML) · Sponsor: Novartis Pharmaceuticals
The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation. The presence of this mutation introduces treatment difficulties due to the limited available options. The study seeks to collect additional data on the effectiveness and safety of asciminib for these patients. By determining the drug's capacity to manage the disease and enhance patients outcomes, the study is designed to fill the unmet medical need and potentially offer a new therapeutic path for patients at a treatment deadlock.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Bordeaux, France | Recruiting |
| Novartis Investigative Site | Lille, France | Recruiting |
| Novartis Investigative Site | Lyon, France | Recruiting |
| Novartis Investigative Site | Nantes, France | Recruiting |
| Novartis Investigative Site | Paris, France | Recruiting |
| Novartis Investigative Site | Vandœuvre-lès-Nancy, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06514534